Trial Profile
Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy. The NivoM Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms NivoM
- 21 Apr 2019 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 New trial record